China-based Hua Medicine plans to focus on the US trial development of its type 2 diabetes (T2D) drug in diabetic kidney ...

The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type ...

It contains compounds like eugenol and ursolic acid, which have been shown to enhance the activity of enzymes involved in carbohydrate metabolism, such as glucokinase, hexokinase, and ...

Angela is passionate about teaching chemistry and conducting undergraduate research. She is a member of the American Society for Biochemistry and Molecular Biology and the Hemingway Society. Bolduc, K ...